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Zika virus (ZIKV) is a mosquito-borne virus that causes Zika fever and neurological 
complications such as Guillain-Barré syndrome and congenital microcephaly. ZIKV 
(family Flaviviridae, genus Flavivirus) is transmitted to humans through the bite of 
infected mosquitoes. Similar to other flaviviruses, ZIKV is a positive-sense, single-
stranded RNA virus and has a 10,794 nucleotide genome. The genome consists of 
structural and non-structural proteins. The envelope (E) glycoprotein is the major structural 
protein of flavivirus which plays an important role in virus entry mechanism and is a major 
target for neutralizing antibodies. The E protein consists of three structurally distinct 
domains; domain I, domain II and domain III. Domain III (EDIII) of the E protein has 
shown strong neutralizing properties that can elicit antibodies. Precursor membrane (prM) 
glycoprotein is one of the structural proteins and it has been shown to form an unusual 
complex with the EDIII protein. This complex is responsible for virus assembly, fusion 
and also immunity-inducing of the virus. One of the non-structural proteins of flaviviruses, 
non-structural 1 (NS1) protein is currently a target for viral biomarkers as it is able to 
induce antibodies production during Zika infection. In this study, the EDIII, prM and NS1 
regions of ZIKV were cloned and expressed using the pET SUMO expression system. 
Methods such as SDS-PAGE and Western blot were used to analyse the expression of each 
recombinant proteins. The recombinant fusion proteins were successfully expressed at their 
approximated molecular weights; EDIII (38.2 kDa), prM (20 kDa), NS1 (dimer 40 kDa 
and monomer 20 kDa). These proteins were then purified using nickel-affinity column 
chromatography and the reactivity of purified recombinant proteins were evaluated in 




both of the assays and the results of this study showed that the recombinant EDIII, prM 
and NS1 fusion proteins have different consistencies in the assays.  
 











Virus Zika (ZIKV) ialah virus bawaan nyamuk yang menyebabkan demam Zika dan 
komplikasi neurologi seperti sindrom Guillain-Barré dan kongenital microcephaly. ZIKV 
(keluarga virus Flaviviridae, genus Flavivirus) menjangkiti manusia melalui gigitan 
nyamuk yang dijangkiti virus tersebut. Serupa dengan flavivirus yang lain, ZIKV 
mempunyai RNA positif yang bebenang tunggal dan mempunyai 10,794 genom nukleotid. 
Genom tersebut mempunyai protein-protein berstruktur dan tidak berstruktur. Protein 
envelope (E) adalah protein berstruktur yang terbesar dalam flavivirus dan memainkan 
peranan penting dalam mekanisma kemasukan virus dan merupakan sasaran untuk 
antibodi yang mampu meneutralkan virus. Protein E terdiri daripada tiga domain iaitu; 
domain I, domain II dan domain III. Domain III (EDIII) telah menunjukkan ciri-ciri 
meneutralkan dan mampu mencungkil antibodi. Protein  precursor membrane (prM) 
adalah salah satu protein berstruktur yang membentuk suatu kompleks dengan protein 
EDIII. Kompleks tersebut bertanggungjawab dalam perhimpunan virus-virus, penyatuan 
dan juga pendorongan imuniti oleh virus. Salah satu daripada protein tidak berstruktur 
dalam flavivirus, non-structural 1 (NS1) protein kini menjadi sasaran untuk viral 
biomarker oleh kerana kemampuan untuk mendorong penghasilan antibodi ketika 
jangkitan Zika. Di dalam kajian ini, region EDIII, prM dan NS1 dalam ZIKV telah diklon 
dan diekspres dalam system pengekspresan pET SUMO. Kaedah-kaedah seperti SDS-
PAGE dan Western blot telah digunakan dalam menilai ekspresi setiap protein 
rekombinan. Protein-protein penyatuan rekombinan tersebut telah berjaya diekspreskan 




kDa dan monomer 20 kDa). Setelah itu, protein-protein ini diaslikan menggunakan 
kromatografi nikel dan kereaktifan diuji dalam asai immunoblot dan ELISA IgG. Terdapat 
20 sampel serum manusia telah diuji dalam kedua-dua asei tersebut dan keputusan 
menunjukkan bahawa protein-protein penyatuan rekombinan EDIII, prM dan NS1 
mempunyai ketekalan yang berbeza dalam asei berkenaan.  
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1.1 Study Background 
 Zika virus (ZIKV) is a member of the virus family Flaviviridae and genus 
Flavivirus. Similar to other flaviviruses such as dengue virus (DENV), yellow fever virus 
and Japanese encephalitis virus (JEV), ZIKV is primarily transmitted by mosquitoes to 
humans. In general, these viruses causes millions of infections in the global population 
annually (Weissenbock et al., 2010). ZIKV was first isolated from a sentinel rhesus 
monkey in the forest of Zika, Uganda (Dick et al., 1952) and first human infection was 
reported from Nigeria in 1954 (Roth et al., 2014). Although ZIKV has been circulating in 
Africa and Asian countries for sixty years (Dick et al., 1952), but the massive outbreaks of 
Zika disease in Yap Island, Micronesia in 2007 caused a major shift in ZIKV epidemiology 
(CDC, 2016). Besides that, major outbreak of the disease surfaced in French Polynesia at 
the end of 2013 and a rise in neurological complications and Guillain-Barré syndrome 
(GBS) was reported (Oehler et al., 2014). The direct association of these complications to 
ZIKV could not be established as there was also the co-circulation of DENV (Roth et al., 
2014).  
 Asian countries are known to be endemic to arboviral diseases and ZIKV infection 
were reported sporadically in the Philippines (Alera et al., 2015), Cambodia (Heang et al., 
2012), Thailand (Buathong et al., 2015) and Indonesia (Olson et al., 1990). Furthermore, 
Malaysia is a dengue-endemic country and has favourable ecological conditions for ZIKV 
transmission. Although serological evidences of ZIKV infections were obtained from 
human samples in the 50s and 90s (Smithburn, 1954), till date there is no recent outbreak 




2014 in a German traveler returning from Sabah, Borneo. It was concluded that in Borneo, 
either the virus only rarely infects humans or it was possibly mistaken for dengue fever 
(Tappe et al., 2015). Similar clinical presentations between ZIKV illness and other 
arboviruses such as dengue and chikungunya may cause diagnostic confusion especially in 
regions where these viruses co-circulate (Duffy et al., 2009; Heang et al., 2012; Ioos et al., 
2014). 
 
1.2 Problem Statement 
 Generally, diagnosis of ZIKV infection is established either in direct method such 
as the detection of viral ribonucleic acid (RNA) by reverse-transcription polymerase chain 
reaction (RT-PCR) or by indirect method to identify the presence of ZIKV-induced 
antibodies (Waggoner & Pinsky, 2016). However, virus detection by RT-PCR is only 
feasible at the beginning phase of infection (Campos et al., 2015). Serological assays of 
ZIKV infection is challenging because of the cross-reactivity with other flaviviruses 
especially in endemic areas (Rabe et al., 2016). The similar antigenic determinants among 
flaviviruses resulted in species-specific and flavivirus cross-reactive antibodies when being 
infected with one flavivirus (Rathore & St. John, 2020). Due to this, a more specific and 
rapid immunodiagnostic tests is still in a great demand (Munoz-Jordan, 2017).   
 
1.3 Objectives 
 The interest of this study therefore, is to investigate the application of the domain 
III of the envelope (EDIII), precursor membrane (prM) and non-structural 1 (NS1) proteins 




immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. This can be achieved 
through the following set of objectives: 
  
 i. To clone EDIII, prM and NS1 region of ZIKV 
 ii. To express and purify recombinant proteins of EDIII, prM and NS1 of  
  ZIKV 
 iii. To evaluate the potential of these recombinant proteins for antibody  
  production 
 
1.4 Chapter Summary 
 The focus of this study was to clone and express EDIII, prM and NS1 target 
regions of ZIKV. The regions were amplified using specific primers designed in this study 
and was cloned in E. coli cloning vector. Positive clones were screened by colony PCR and 
the selected clone was verified by deoxyribonucleic acid (DNA) sequencing. Then, the 
recombinant proteins were expressed and purified using nickel-affinity column 
chromatography. At the end of this study, the reactivity of the purified recombinant 
proteins were evaluated in immunoblot assays and also tested against human sera in 
indirect IgG ELISA.  






2.1 Zika virus 
 ZIKV is a member of the Flaviviridae family, in the genus Flavivirus. It was first 
isolated from rhesus monkeys in the forest of Zika, Uganda in the 1940s (Dick et al., 1952) 
and the first case of human infection was reported in Nigeria a decade later (Macnamara, 
1954). Dengue virus (DENV) and Japanese encephalitis virus (JEV) are among the 
mosquito-borne viruses from the same family as ZIKV (Weissenbock et al., 2010). Every 
year, millions of infections caused by these viruses were reported across the globe 
(Weissenbock et al., 2010). There is no cure for Zika virus disease at the moment, and 
treatment is focused on relieving the symptoms. To date, the development of a ZIKV 
vaccine is still in progress (WHO, 2018). 
 
2.2 ZIKV epidemiology 
 The first case of ZIKV infection in humans was recorded in Nigeria in 1954 
(Macnamara, 1954). For decades, ZIKV is known to cause only sporadic human infections 
in Africa and Asia. The first major outbreak was reported in Yap Island, Micronesia in 
2007 (Duffy et al., 2009). In October 2013, the second major outbreak of ZIKV occurred 
in French Polynesia, causing over 30,000 patients to seek medical attention in health-care 
facilities (Roth et al., 2014). During this outbreak, increased incidence of neurological 
complications and Guillain-Barré syndrome (GBS) was observed and this was being 
associated with ZIKV infection. However, this association requires further investigations 




Following the outbreak in French Polynesia, ZIKV infections were also reported in Cook 
Islands, New Caledonia and Easter Island, confirming the ability of this virus to spread 
outside of African and Asian regions (Roth et al., 2014). In May 2015, Brazil’s National 
Reference Laboratory reported the first local infection of ZIKV and subsequent spread of 
the virus has affected about 1.5 million people (European Centre for Disease Prevention 
and Control, 2015a). With the exception of Europe, ZIKV has circulated to all other 
continents of the world (Boyer et al., 2018). 
 ZIKV infection has been described as sporadic in Asia, particularly Indonesia 
(Olson et al., 1990), Cambodia (Heang et al., 2012), Philippines (Alera et al., 2015) and 
Thailand (Buathong et al., 2015). In 2010, a 3-year-old Cambodian boy was reported with 
ZIKV infection of a strain closely related to the ones responsible in the Yap Island 
outbreak, both possibly share an ancestor that was isolated in Malaysia in 1966 (Boyer et 
al., 2018). This shows that the virus could be expanding its geographical distribution 
(Haddow et al., 2012). In Peninsular Malaysia, although ZIKV was previously detected in 
Aedes aegypti mosquitoes (Marchette et al., 1969) and antibodies against the virus were 
also detected in serum samples from patients (Smithburn, 1954), there is no recent report 
of Zika fever in the country. However, Tappe et al. (2015) reported an acute ZIKV 
infection in a German traveler after a trip to Sabah and Peninsular Malaysia in 2014. IgM 
and IgG to ZIKV were found to be present in the patient’s blood through indirect 
immunofluorescence assay in the early stage of infection. Later on, ZIKV-specific 
neutralizing antibodies were also detected in viral neutralization testing. 
The spread of ZIKV infection to the global population is similar to that of the other 
arboviruses such as DENV and CHIKV (Musso et al., 2015). It is common that ZIKV 
outbreak being initially misdiagnosed as dengue fever due to the similarity of symptoms 
